ARAnastasiia Russkikh

Anastasiia Russkikh

*This is an algorithmically generated author record based on publicly available information.

Anastasiia Russkikh has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Irina A. Vasilyeva

    National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health

    4 shared publications
  • O. V. Lovacheva

    National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Ministry of Health of the Russian Federation

    4 shared publications
  • Anastasiya G. Samoylova

    National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Ministry of Health of the Russian Federation

    3 shared publications
  • Alexandra Gracheva

    Federal State Budgetary Institution "National Medical Research Center of Phthisiopulmonology and Infectious Diseases" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation

    2 shared publications
  • Irina Vasilyeva

    Federal State Budgetary Institution "National Medical Research Center of Phthisiopulmonology and Infectious Diseases" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation

    2 shared publications
  • Anastasia Samoilova

    Federal State Budgetary Institution "National Medical Research Center of Phthisiopulmonology and Infectious Diseases" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation

    1 shared publication

Latest Publications

  • Open Access

    Treatment of Mycobacteriosis with Lung Destruction Using Long-Term Endobronchial Valve Implantation

    by O. V. Lovacheva, А. E. Russkikh, А. N. Gracheva, А. E. Panova, А. G. Samoylova, I. А. Vasilyeva

    The article describes a case of effective treatment of fibrous cavernous pulmonary mycobacteriosis with the implantation of the endobronchial valve (valve bronchial block).Subjects and Methods. A 66-year-old man was diagnosed with fibrous cavernous pulmonary mycobacteriosis. M. chelonae was detected as a causative agent of the disease. At the time of diagnosis, the disease lasted for 12 months, the duration of treatment due to the erroneous diagnosis of tuberculosis made 6.5 months, the drug therapy of mycobacteriosis lasted for 11 months, and after development of the adverse event in the form of constant tinnitus, the patient interrupted the drug therapy. The patient received no drug therapy for 24 months before the implantation of the endobronchial valve.Result. The cure of mycobacteriosis and cavity healing were achieved after the implantation of the endobronchial valve. The endobronchial valve remained in the bronchus for 22 months. During this period and after the removal of the endobronchial valve, the patient did not take any medications, lived an active life and was managed on an outpatient basis.


  • The effectiveness of broncho-alveolar lavage for the pathogen detection in children with pulmonary tuberculosis

    by Anastasiia Russkikh, Elena Veselova, Olga Lovacheva, Nadezda Klevno, Anna Panova, Alexandra Gracheva, Anastasia Samoilova, Irina Vasilyeva

    Diagnosis and treatment for pulmonary tuberculosis (TB) among children and adolescents is difficult without pathogen identification. Objective: To define the effectiveness of Mycobacteria tuberculosis (MTB) detection via broncho-alveolar lavage fluid (BALF) assay among children and adolescents with pulmonary TB. Methods: 35 patients with pulmonary TB were examined: 12 - at the age of 3-7 years, 5 - 8-13 years and 18 - 14-17 years. All of them were MTB culture negative and had negative rapid molecular tests (RMT) results for MBT from sputum samples or were unable to produce sputum. BAL from the affected area was performed via bronchoscopy. Depending on the age, the total volume of the administered saline solution varied from 15 ml (for 3-4-year-olds) to 80 ml (for 15-17-year-olds). MTB detection in BALF was performed via RMT, liquid culture testing ("BACTEC MGIT 960") and smear microscopy (SM). Results: MTB were detected in the BALF via SM in 3/35 (8.6%) patients. 4/35 (11.4%) - were MTB culture positive from BALF. The most effective method was RMT. MTB DNA was detected in 21/35 (60.0%): among aged 3-7 years - in 4/12 (33.3%), 8-13 years - in 4/5 (80%), 14-17 years - in 13/18 (72.2%). 3/21 (14,3%) (11, 15, 15 years old) children were diagnosed with multidrug-resistant TB. All 4 culture positive patients had also positive RMT results from BALF samples, in 2 cases positive results were obtained by all three methods. Conclusions: BAL improves the effectiveness of MBT detection in children and adolescents with pulmonary TB without MTB positive sputum samples by 60 % (95%CI: 43.6 -74.5) Wilson9s method) due to RMT. Depending on the age, the effectiveness ranges from 33.3% to 80%.

  • Open Access

    Short course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectives

    by A. E. Russkikh, D. M. Kutuzova, O. V. Lovacheva, A. G. Samoylova, I. A. Vasilyeva

    The article presents a review of 70 publications. It describes relevant data on drugs, timing, indications, efficacy, and safety of short-term treatment regimens for multiple drug resistant tuberculosis.


  • Open Access

    Factors associated with culture conversion among adults treated for pulmonary extensively drug-resistant tuberculosis during 2018-2019 in the Russian Federation: an observational cohort study

    by Anastasiia Russkikh, Oleksandr Korotych, Yuliia Sereda, Anastasia Samoilova, Jay Achar, Askar Yedilbayev, Masoud Dara, Irina Vasilyeva

    Treatment outcomes for Multidrug/Rifampicin-Resistant Tuberculosis (MDR/RR-TB) and Extensively Drug-Resistant Tuberculosis (XDR-TB) remain poor across the globe and in the Russian Federation. Treatment of XDR-TB is challenging for programmes and patients often resulting in low success rates and onward transmission of drug-resistant strains. Analysis of factors affecting culture conversion rate among XDR-TB patients may serve as a basis for optimization of treatment regimens. We conducted a retrospective cohort study using health records from 54 patients with pulmonary XDR-TB treated at a tertiary level facility in the Russian Federation. The study population included adult patients with culture-positive pulmonary XDR-TB who started treatment between 1 January 2018-30 June 2019. Culture conversion was defined as two consecutive negative cultures, collected at least 30 days apart. The date of sputum culture conversion was taken from the first of two consecutive negative sputum cultures fulfilling these criteria. We measured time to culture conversion using cumulative incidence functions accounting for competing risks and applied binary cause-specific Cox regressions to assess associated factors. Sputum culture conversion was recorded for 43 (79.6%) patients. Median time to culture conversion adjusted for competing risk of loss to follow up was 4 months [95% confidence interval (CI): 2–5]. The number of patients who had culture converted by treatment months 2, 4, and 6 were 12 (22%), 29 (54%) and 38 (70%) respectively. In unadjusted analysis, positive baseline sputum smear microscopy [hazard ratio (HR): 0.34, 95% CI: 0.18-0.66; p=0.001), hepatitis C (HR: 0.35, 95% CI: 0.14-0.89; p=0.023], and human immunodeficiency virus (HR: 0.30 95%, CI: 0.09-0.97; p=0.045), and receipt of fewer than 4 effective drugs in the treatment regimen (HR: 0.13, 95% CI: 0.03-0.60; p=0.009) were associated with delayed culture conversion. When compared to their combined use, patients receiving regimens with bedaquiline only (HR: 0.12, 95% CI: 0.03-0.49; p=0.003) or linezolid only (HR: 0.21, 95% CI: 0.06-0.69; p=0.010) were less likely to achieve timely culture conversion. Factors delaying sputum culture conversion should be considered in the management of patients with XDR-TB and considered by clinicians for regimen design and treatment strategies. Our study outlines the importance of simultaneous inclusion of bedaquiline and linezolid in treatment regimens for patients with XDR-TB to reduce time to sputum conversion and increase treatment success.


  • Open Access

    Novel coronavirus infection

    by E. I. Veselova, A. E. Russkikh, G. D. Kaminskiy, O. V. Lovacheva, A. G. Samoylova, I. A. Vasilyeva

    The article presents the review of 59 publications describing the aspects of etiology, pathogenesis, diagnostics, and treatment of COVID-19 caused by SARS-CoV-2 coronavirus.The authors state that they have no conflict of interests.


  • Endobronchial valve treatment for cavitary pulmonary diseases caused by non-tuberculosis mycobacteria

    by Anastasiia Russkikh, Alexandra Gracheva, Olga Lovacheva, Irina Vasilyeva

    Introduction: Failures in the treatment of non-tuberculous mycobacterial pulmonary diseases (NTM-PD) are often associated with the long-term treatment and intolerance of drug therapy regimens by patients, all of which require the development of new alternative treatments. Objective of Study: Define possibility of application endobronchial valves (EBV) for the treatment of cavitary NTM-PD in patients with intolerance of antibacterial therapy. Materials and Methods: 5 patients (male - 3, female - 2) with cavitary NTM-PD at whom antibacterial therapy (ABT) was discontinued due to intolerance after less than 14 days. Then installation of EBV (MedLung, Russia) was performed through fibrobronchoscopy (FBS), but ABT therapy hasn’t been resumed. All patients were urban residents, their mean age was 38,2 years. 3 patients had a unilateral, 2- bilateral. The largest cavity was 31 х 44 mm. No complications occurred during EBV application. The growth of the non-tuberculosis mycobacteria (NTMB) was obtained from sputum or bronchoalveolar lavage (BL) liquid at the solid media. Species of NTMB were identified using DNA-strips (Hain Lifescience). M. avium was identified in 2 cases, M. xenopi -1, M. chelonae -1, M. kansasii -1. Results: Duration of EBV treatment was 8-13 months, then EBV was removed with FBS. Resorption of infiltrates during period of the treatment occurred in all of patients (100 %), cavity closures were recorded in 4/5 (80%) cases. One patient had remaining thin-walled cavity. NTMB in sputum or BL fluid samples were not detected by any method. Conclusion: EBV treatment can be used successfully for closure of the cavities in NTM-PD, even if it isimpossible to carry out drug therapy.